One share of CRTX stock can currently be purchased for approximately $39.85.Cortexyme has a market capitalization of $1.17 billion. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Following the acquisition, the director now directly owns 301,829 shares of the company’s stock, valued […] Reserve your FREE copy of "The Top 5 Cannabis Stocks that Belong on Your Watchlist".Cortexyme has received a consensus rating of Buy. The …
Cortexyme earned a news sentiment score of 1.5 on InfoTrie's scale. Approximately 13.0% of the shares of the stock are short sold. The shares were bought at an average cost of $55.08 per share, with a total value of $478,645.20. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." This suggests a possible upside of 71.5% from the stock's current price. Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders.
Cortexyme, Inc. will issue more than 4.41 million shares on the Nasdaq under ticker CRTX, according to the firm’s S-1 filing. Company insiders that have bought Cortexyme stock in the last two years include David Lamond, Epiq Capital Group, Llc, and Pfizer Inc. Shares of CRTX can be purchased through any online brokerage account.
The previous year saw a loss of $12.24 million. And they’re discussing something that no one’s ever seen before.Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Operating expenses: Research and development $ 4,825 $ 2,413 . Four new biotechs hit the market May 9. The biopharmaceutical company reported ($0.61) EPS for the quarter, missing the Zacks' consensus estimate of ($0.45) by $0.16. © American Consumer News, LLC dba MarketBeat® 2010-2020. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. All rights reserved.
347 . Sign-up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.Cortexyme's stock was trading at $37.02 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Learn about financial terms, types of investments, trading strategies and more.MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. CRTX stock was bought by a variety of institutional investors in the last quarter, including EPIQ Capital Group LLC, SG Americas Securities LLC, Strs Ohio, and Signaturefd LLC. One share of CRTX stock can currently be purchased for approximately $39.85.Cortexyme has a market capitalization of $1.17 billion. The bacterial pathogen has been found in the brains of more than 90 percent of Alzheimer’s patients, according to the firm’s prospectus.In 2018, Cortexyme recorded a net loss of $12.48 million. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future.